Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Respiratory Research
Published in: Respiratory Research 1/2016

Open Access 01-12-2016 | Research

IL-25 and IL-33 induce Type 2 inflammation in basophils from subjects with allergic asthma

Authors: Brittany M. Salter, John Paul Oliveria, Graeme Nusca, Steve G. Smith, Damian Tworek, Patrick D. Mitchell, Rick M. Watson, Roma Sehmi, Gail M. Gauvreau

Published in: Respiratory Research | Issue 1/2016

Login to get access

Abstract

Background

The alarmin cytokines IL-25 and IL-33 are key promoters of type 2 inflammation. Basophils respond to alarmin cytokines, however the relationship of these cytokines with basophil activation and recruitment in human studies of allergic asthma has not been well characterized. This study investigated the effect of IL-25 and IL-33 on basophils in a model of allergic asthma.

Methods

10 mild allergic asthmatics underwent allergen and diluent inhalation challenges. Bone marrow aspirates were collected at pre-challenge and 24 h (h) post challenge. Peripheral blood and sputum samples were collected at pre-challenge, 7 h, and 24 h post-challenge to measure basophil expression of IL-17RB, ST2, and intracellular IL-25. Freshly isolated peripheral blood basophils from allergic donors were incubated overnight with IL-25 and IL-33, or sputum supernatant collected post-allergen to assess pro-inflammatory effects of mediators released in the airways.

Results

There were increased percentage of basophils expressing IL-17RB, ST2, and intracellular IL-25 collected from bone marrow, peripheral blood, and sputum after allergen inhalation challenge. In vitro stimulation with IL-25 and IL-33 increased the percentage of basophils expressing intracellular type 2 cytokines and surface activation markers, and primed eotaxin-induced migratory potential of basophils, which was mediated directly through IL-17RB and ST2, respectively. Stimulation of basophils with sputum supernatants collected post-allergen challenge up-regulated the percentage of basophils expressing markers of activation and intracellular type 2 cytokines, which was reversed following blockade of the common β chain (βc).

Conclusions

Our findings indicate that the alarmin cytokines IL-33 and IL-25 increase basophil activation and migratory potential, and may pose as a novel therapeutic targets for the treatment of allergic asthma.
Appendix
Available only for authorised users
Literature
1.
Yao XJ, Huang KW, Li Y, Zhang Q, Wang JJ, Wang W, et al. Direct comparison of the dynamics of IL-25- and ‘allergen’-induced airways inflammation, remodelling and hypersensitivity in a murine asthma model. Clin Exp Allergy. 2014;44(5):765–77.PubMedCrossRef
2.
Angkasekwinai P, Srimanote P, Wang YH, Pootong A, Sakolvaree Y, Pattanapanyasat K, et al. Interleukin-25 (IL-25) promotes efficient protective immunity against Trichinella spiralis infection by enhancing the antigen-specific IL-9 response. Infect Immun. 2013;81(10):3731–41.PubMedPubMedCentralCrossRef
3.
Zhiguang X, Wei C, Steven R, Wei D, Wei Z, Rong M, et al. Over-expression of IL-33 leads to spontaneous pulmonary inflammation in mIL-33 transgenic mice. Immunol Lett. 2010;131(2):159–65.PubMedCrossRef
4.
Imai Y, Yashua K, Sakaguchi Y, Haneda T, Mizutani H, Yoshimoto T, et al. Skin-specific expression of IL-33 activated group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice. Proc Natl Acad Sci U S A. 2013;110(34):1391–26.CrossRef
5.
Tamachi T, Maezawa Y, Ikeda K, Kagami S, Hatano M, Seto Y, et al. IL-25 enhances allergic airway inflammation by amplifying a TH2 cell-dependent pathway in mice. J Allergy Clin Immunol. 2006;118(3):606–14.PubMedCrossRef
6.
Kondo Y, Yoshimoto T, Yasuda K, Futatsugi-Yumikura S, Morimoto M, Hayashi N, et al. Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int Immunol. 2008;20(6):791–800.PubMedCrossRef
7.
Ballantyne SJ, Barlow JL, Jolin HE, Nath P, Williams AS, Chung KF, et al. Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma. J Allergy Clin Immunol. 2007;120(6):1324–31.PubMedCrossRef
8.
Rickel EA, Siegel LA, Yoon BR, Rottman BJB, Kugler DG, Swart DA, et al. Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities. J Immunol. 2008;181(6):4299–310.PubMedCrossRef
9.
Liu X, Li M, Wu Y, Zhou Y, Zeng L, Huang T. Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma. Biochem Biophys Res Commun. 2009;386(1):181–5.PubMedCrossRef
10.
Lee HY, Rhee CK, Kang JY, Byun JH, Choi JY, Him SJ, et al. Blockade of IL-33/ST2 ameliorates airway inflammation in a murine model of allergic asthma. Exp Lung Res. 2014;40(2):66–76.
11.
Kim J, Kim W, Le HT, Moon UJ, Tran VG, Kim HJ, et al. IL-33-induced hematopoietic stem and progenitor cell mobilization depends upon CCR2. J Immunol. 2014;193(7):3792–802.
12.
Iikura M, Suto H, Kajiwara N, Oboki K, Ohno T, Okayama Y, et al. IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest. 2007;87:971–8.
13.
Allakhverdi Z, Smith DE, Comeau MR, Delespesse G. Cutting edge: the ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol. 2007;179:2051–4.PubMedCrossRef
14.
Moritz DR, Rodewald HR, Gheyselinck J, Klemenz R. The IL-1 receptor-related T1 antigen is expressed on immature and mature mast cells and on fetal blood mast cell progenitors. J Immunol. 1998;161:4866–74.PubMed
15.
Kurowska-Stolarska M, Kewin P, Murphy G, Russo RC, Stolarski B, Garcia CC, et al. IL-33 induces antigen-specific IL-51T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol. 2008;181:4780–90.
16.
Smithgall MD, Comeau MR, Yoon BR, Kaufman D, Armitage R, Smith DE. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen reactive Th2 cells, iNKT and NK Cells. Int Immunol. 2008;20:1019–30.
17.
Cherry WB, Yoon J, Bartemes KR, Iijima K, Kita H. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol. 2008;121:1484–90.PubMedPubMedCentralCrossRef
18.
Suzukawa M, Koketsu R, Iikura M, Nakae S, Matsumoto K, Nagase H, et al. Interleukin-33 enhances adhesion, CD11b expression and survival in human eosinophils. Lab Invest. 2008;88:1245–53.
19.
Coyle AJ, Lloyd C, Tian J, Nguyen T, Erikkson C, Wang L, et al. Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J Exp Med. 1999;190:895–902.
20.
Eiwegger T, Akdis CA. IL-33 links tissue cells, dendritic cells and Th2 cell development in a mouse model of asthma. Eur J Immunol. 2011;41(6):1535–8.PubMedCrossRef
21.
Tang W, Smith SG, Beaudin S, Dua B, Howie K, Gauvreau G, et al. IL-25 and IL-25 receptor expression on eosinophils from subjects with allergic asthma. Int Arch Allergy Immunol. 2014;163(1):5–10.
22.
Babu J, Lombardi V, Akbari O, Barbers R. Expression of IL-25 receptors on iNKTS cells from patients with severe asthma. Chest. 2011;140(4):228A.CrossRef
23.
Prefontaine D, lajoie-Kadoch S, Foley S, Audusseau S, Olivenstein R, Halayko AJ, et al. Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J Immunol. 2009;183(3):5094–103.
24.
Prefontaine D, Nadigel J, Chouiali F, Audusseau S, Semlali A, Chakir J, et al. Increased IL-33 expression by epithelial cells in bronchial asthma. J Aller Clin Immunol. 2010;125(3):752–4.
25.
Azazi E, Elshora A, Tantawy E, et al. Serum levels of Interleukin-33 and its soluble receptor ST2 in asthmatic patients. Egyt J Chest Dis Tuberc. 2014;63(2):279–84.CrossRef
26.
Corrigan C, Wang W, Meng Q, Fang C, Eid G, Caballero MR, et al. Allergen-induced expression of IL-25 and Il-25 receptor in atopic asthmatic airways and late-phase cutaneous responses. J Allergy Clin Immunol. 2011;128(1):116–24.
27.
Gauvreau GM, Lee JM, Watson RM, Irani AM, Schwartz LB, O'Byrne PM. Increased numbers of both airway basophils and mast cells in sputum after allergen inhalation challenge of atopic asthmatics. Am J Respir Crit Care Med. 2000;161(5):1473–8.PubMedCrossRef
28.
Salter BM, Oliveria J, Nusca G, Smith SG, Watson RM, Comeau M, et al. Thymic Stromal Lymphopoietin Activation of Basophils in Allergic Asthma is IL-3 Dependent. J Allergy and Clin Immunol. 2015;136(6):1636–44.
29.
Watson BM, Oliveria JP, Nusca GM, Smith SG, Beaudin S, Dua B, et al. Inhibition of Allergen-Induced Basophil Activation by ASM-024, a Nicotinic Receptor Ligand. Int Arch Allergy Immunol. 2014;165(4):255–64.
30.
Ocmant A, Michils A, Schandene L, Peignois Y, Goldman M, Stordeur P. IL-4 and IL-13 mRNA real time PCR quantification on whole blood to assess allergic response. Cytokine. 2005;31:375–81.
31.
Pecaric-Petkovic T, Didchenko SA, Kaempfer S, Spiegl N, Dahinden CA. Human basophils are the direct target leukocytes of the novel IL-1-family member IL-33. Blood. 2009;113:1526–34.PubMedPubMedCentralCrossRef
32.
Rivellese F, Suurmond J, de Paulis A, Marone G, Hujinga TW, Toes RE. IgE and IL-33-mediated triggering of human basophils inhibits TLR4-induced monocyte activation. Eur J Immunol. 2014;44:3045–55.PubMedCrossRef
33.
Suzukawa M, Iikura M, Koketsu R, Nagase H, Tamura C, Komiya A, et al. An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor. J Immunol. 2008;181:5981–9.
34.
35.
Wang YH, Angkasekwinai P, Lu N, Voo KS, Arima K, Hanabuchi S, et al. IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells. J Exp Med. 2007;204(8):1837–47.
36.
Wang H, Mobini R, Gang Y, Barrenas F, Zhang H, Xiang Z, et al. Allergen challenge of peripheral blood mononuclear cells from patients with seasonal allergic rhinitis increase IL-17RB, which regulates basophil apoptosis and degranulation. Clin Exper Allergy. 2010;40:1194–202.
37.
Cockcroft DW. Measure of airway responsiveness to inhaled histamine or methacholine; method of continuous aerosol generation and tidal breathing inhalation. In: Hargreave FE, Woolcock AJ, editors. Airway responsiveness: measurement and interpretation. Mississauga: Astra Pharmaceuticals Canada Ltd; 1985. p. 22–8.
38.
O’Byrne PM, Dolovich J, Hargreave FE. Late asthmatic responses. Am Rev Respir Dis. 1987;136(3):740–51.PubMedCrossRef
39.
Bafadhel M, McCormick M, Saha S, McKenna S, Shelleyy M, Hargadon B, et al. Profiling of sputum inflammatory mediators in asthma and chronic obstructive pulmonary disease. Respiration. 2010;83:36–44.
40.
Stirling RG, Rensen ELJ, Barnes PJ, Chung KF. Interleukin-5 induces CD34+ eosinophil progenitor mobilization and eosinophil CCR3 expression in asthma. Am J Respir Crit Care Med. 2001;8:1403–9.CrossRef
41.
Dorman SC, Babirad I, Post J, Watson RM, Foley R, Jones GL, et al. Progenitor egress from the bone marrow after allergen challenge: Role of stromal cell-derived factor 1alpha and eotaxin. J Allergy Clin Immunol. 2005;115(3):501–6.
42.
Nagarkar DR, Poposki JA, Tan BK, Comeau MR, Peters AT, Hulse KE, et al. Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2013;132(3):593–600.
43.
Fux M, Pecaric-Petkovic T, Odermatt A, Hausmann OV, Lorentz A, Bischoff SC, et al. IL-33 is a mediator rather than a trigger of the acute allergic response in humans. Allergy. 2014;69(2):216–22.PubMedCrossRef
44.
Heineman A, Hartnell A, EL Stubs V, Murakami K, Soler D, LaRosa G, et al. Basophil responses to chemokines regulated by both sequential and cooperative receptor signaling. J Immunol. 2000;165:7225–33.CrossRef
Metadata
Title
IL-25 and IL-33 induce Type 2 inflammation in basophils from subjects with allergic asthma
Authors
Brittany M. Salter
John Paul Oliveria
Graeme Nusca
Steve G. Smith
Damian Tworek
Patrick D. Mitchell
Rick M. Watson
Roma Sehmi
Gail M. Gauvreau
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2016
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-016-0321-z

Other articles of this Issue 1/2016

Respiratory Research 1/2016 Go to the issue

Research

TNF-α and IL-1β-activated human mesenchymal stromal cells increase airway epithelial wound healing in vitro via activation of the epidermal growth factor receptor

Research

Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis

Letter to the Editor

How to achieve safe, high-quality clinical studies with non-Medicinal Investigational Products? A practical guideline by using intra-bronchial carbon nanoparticles as case study

Research

CXCL13 in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension

Research

High resolution metabolomics to discriminate compounds in serum of male lung cancer patients in South Korea

Research

Differential DNA methylation marks and gene comethylation of COPD in African-Americans with COPD exacerbations

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits